Alkermes plc.
Ticker: ALKSHealthcarePharmaceutical PreparationsThe business
Alkermes plc (NASDAQ: ALKS) is a global biopharmaceutical company headquartered in Ireland with corporate offices and research and development operations in Massachusetts and a manufacturing facility in Ohio. The company focuses on developing innovative medicines in neuroscience, addressing unmet needs in neurological and psychiatric disorders.
The company's marketed product portfolio includes ARISTADA and ARISTADA INITIO for schizophrenia treatment, LYBALVI for schizophrenia and bipolar I disorder, VIVITROL for alcohol and opioid dependence, and LUMRYZ for narcolepsy. LUMRYZ was acquired through the completion of the Avadel Acquisition in February 2026, which added both a proprietary commercial product and an experienced commercial organization to Alkermes' operations. The company also generates significant revenues through collaborative arrangements and royalties from third-party licensees who commercialize products incorporating Alkermes' proprietary technologies, including the long-acting INVEGA products and RISPERDAL CONSTA marketed by Janssen, and VUMERITY marketed by Biogen.
Alkermes' core competitive advantages center on its proprietary technology platforms, which include injectable extended-release microsphere technology, LINKERX technology for extended-release antipsychotics, NANOCRYSTAL technology for poorly water-soluble compounds, oral controlled release technologies, and MICROPUMP technology for modified-release oral formulations. These platforms enable the development of novel drug formulations with extended duration of action and improved patient outcomes.
The company's research and development pipeline includes alixorexton, a selective orexin 2 receptor agonist in development for narcolepsy and idiopathic hypersomnia, which received FDA Breakthrough Therapy designation in December 2025. Alkermes also evaluates LUMRYZ for additional indications beyond narcolepsy.
Revenues from collaborative arrangements with Janssen and Biogen represented approximately 9% and 9% of consolidated revenues respectively for the year ended December 31, 2025. The company manufactures its proprietary products at its Wilmington, Ohio facility and outsources certain manufacturing operations to contract manufacturers. In May 2024, Alkermes completed the sale of its research and development business and manufacturing facility in Athlone, Ireland to Novo Nordisk.
- Sector
- Healthcare
- Industry
- Pharmaceutical Preparations
- HQ
- DUBLIN 4, L2
- FY end
- 12-31
- CIK
- 1520262
- SIC
- 2834
Ownership
Who holds Alkermes plc. — across funds, superinvestors and bonds · N-PORT 2026Q2 · 13F 2026-06-30
Top fund holders
| Fund | % of fund | Value |
|---|---|---|
| VANGUARD TOTAL STOCK MARKET INDEX FUND VTI · VANGUARD INDEX FUNDS | 0.01% | $277.56M |
| VANGUARD SMALL-CAP INDEX FUND VB · VANGUARD INDEX FUNDS | 0.11% | $200.35M |
| Avantis U.S. Small Cap Value ETF AVUV · American Century ETF Trust | 0.51% | $137.83M |
| VANGUARD SMALL-CAP GROWTH INDEX FUND VBK · VANGUARD INDEX FUNDS | 0.25% | $115.39M |
| VANGUARD EXTENDED MARKET INDEX FUND VXF · VANGUARD INDEX FUNDS | 0.10% | $100.16M |
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Go deeper in your own AI
15 years of statements, narrative and filings — queryable over MCP.
Professionals can also use the built-in AI chat (subscription + your own Anthropic key).
15 years of Alkermes plc.'s financials
Income statement, balance sheet and cash flow across 15 years, every filing with its disclosures, and each number traceable to the filing it came from — free with an account, no card required.
Sign in free